SQLite Web: event_store.db

Update row 478280 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-22T03:03:32.063787+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:4a9d7ba177e2c298","evidence_event_ids":["evt_39799d3a313c"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000020.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000020.txt","company":"Xeris Biopharma Holdings, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000020.txt","article_chars":2414,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_6a201c35d252c229","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000020.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:06:16.537440+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"xers-20260420","final_url":"https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000020.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000020.txt","source_event_id":"evt_39799d3a313c","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"8199027864d7d138","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-20","2021","2026 Annual Meeting","2026-04-22T03:03:32.063787+00:00"],"entities":[{"asset_class":"equity","name":"Xeris Biopharma Holdings, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"other","name":"Dr. Jeffrey Sherman","relevance":"high","symbol":"","type":"person"},{"asset_class":"other","name":"Board of Directors of Xeris Biopharma Holdings, Inc.","relevance":"medium","symbol":"","type":"governance_body"},{"asset_class":"other","name":"Compensation Committee","relevance":"medium","symbol":"","type":"committee"},{"asset_class":"other","name":"Nominating and Corporate Governance Committee","relevance":"medium","symbol":"","type":"committee"},{"asset_class":"other","name":"2026 Annual Meeting of Stockholders","relevance":"medium","symbol":"","type":"event"}],"event_type":"conflict","information_gaps":["The specific SEC 8-K item number is not explicitly shown in the provided text (only the section header 'Item 5.02' appears).","No prior known state is included in the prompt, so the exact 'delta vs prior state' beyond the fact of this retirement cannot be quantified.","No details are provided about whether a replacement director will be appointed or how committee membership will change after the 2026 Annual Meeting."],"key_facts":["The filing is a Form 8-K (Current Report) by Xeris Biopharma Holdings, Inc.","Date of report / earliest event reported: April 20, 2026.","Dr. Jeffrey Sherman is a member of the Board and provided notice of his decision to retire from the Board and not stand for reelection at the 2026 Annual Meeting.","Dr. Sherman has served as a director since 2021.","Dr. Sherman is a member of the Compensation Committee and the Nominating and Corporate Governance Committee.","Dr. Sherman will continue to serve in those committee roles until his term as director expires at the 2026 Annual Meeting.","The Board approved a reduction in the size of the Board from eight to seven directors, effective as of the expiration of Dr. Sherman\u2019s term at the 2026 Annual Meeting.","The filing states Dr. Sherman\u2019s decision was not due to any disagreement with the Company or its management on matters relating to the Company\u2019s operations, policies, or practices."],"numeric_claims":[{"label":"Board size reduction","value":"8 to 7 directors"}],"primary_claim":"On April 20, 2026, Dr. Jeffrey Sherman notified Xeris that he will retire from the Board and not stand for reelection at the 2026 Annual Meeting, and the Board approved reducing the Board size from eight to seven directors effective when his term expires.","relevance_score":0.45,"sentiment":"neutral","source_quality":"high","summary":"Xeris Biopharma Holdings, Inc. filed a Form 8-K on April 20, 2026 reporting the retirement of director Jeffrey Sherman and the resulting reduction in board size from eight to seven directors effective at the 2026 Annual Meeting.","topics":["8-K","board of directors","director retirement","corporate governance","committee membership","annual meeting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Xeris Biopharma Holdings, Inc. \u00b7 Filed 20260421","ticker":"XERS","tickers":["XERS"],"title":"XERS filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000020.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel